SAP-001 is a novel, clinical stage (IIb) small molecule designed to address the large and growing unmet medical needs associated with refractory and tophaceous gout. We believe that SAP-001 is the First-in-Class to offer a complete solution for gout and hyperuricemia, and has the potential to become the Best-in-Class treatment for refractory and/or tophaceous gout patients and for patients that are not well controlled on allopurinol and/or febuxostat, a sizable market with a revenue potential of...

Chronic pruritus occurs in 13% of the global population without age limitation¹, leading to great impairment of quality of life.² There is a high unmet need here as effective treatment options are still missing.